News

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Some patients who switched appear to have done so in anticipation of clinical indications.

Recent breakthrough infections have experts looking closely at the true risks of the COVID-19 delta variant and how we can protect ourselves.

Findings also showed that women had a lower risk of testing positive than men.

With the US federal government health agencies discussing plans for a booster dose for Americans and WHO’s call for a moratorium on these shots, a tale of two vaccine strategies is emerging.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.

Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.

Contagion Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the quick evolution of this variant and how vaccination rates have influenced this COVID-19 strain.

With the FDA nod, Regeneron’s monoclonal antibody Regen-Cov (casirivimab and imdevimab) is authorized for the use of the therapy for post-exposure prophylaxis in certain people exposed to SARS-CoV-2 or who are at high risk of exposure to an infected individual.

As the international world struggles to get first doses, the World Health Organization Director General Tedros Adhanom Ghebreyesus says this should also include high-risk populations.

A report says the timetable is for Labor Day or sooner.

Over the last 4 weeks there has been an 80% increase in the continent and the Delta variant is the large cause according to the World Health Organization (WHO).

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Patients failed to respond to currently available drugs in initial documented instances of spread.

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

Ownership language showed an additional boost in appointment and vaccination rates.

Fever was found to not be an early feature of disease.

An early warning system could help significantly help health systems and public officials to prepare.

Three HIV screening strategies identified comparable numbers of new HIV diagnoses, a new study found.

A seven-day course of antibiotics was as effective as 14 days in treating urinary tract infection in afebrile men.

Patients given a 600 mg injection of cabotegravir still had detectable levels of the drug in plasma, tissues, and fluids for 12 weeks.

What are the efforts being made with antibiotic stewardship and treatments, and what areas in clinical care do medical professionals want to see improvements.

More and more evidence is pointing towards persistent neuropsychiatric symptoms in people who had the disease.

The study found that ¾ of the cases occurred in fully vaccinated individuals.

Reasons given for not vaccinating were safety issues and low risk for infection.

A conversation with Anna Legreid Dopp, Pharm. D.

With new mask guidance comes questions and confusion, especially with the new strain of COVID-19 and those who have been vaccinated.

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.